IFN-γ signaling through the JAK-STAT pathway is not only relevant for cancer immunotherapy, but also underpins pathology in myeloproliferative neoplasms, chronic mucocutaneous candidiasis, primary immunodeficiency, and several inflammatory diseases.1 This evidence concerns the gene IFNG and myeloproliferative neoplasm.